LUND, Sweden — /October 24, 2018/ — SAGA Diagnostics announces today that we have been selected as a Worldwide Top 500 Startup! Out of many thousands of companies from over 100 countries screened, we were chosen by Hello Tomorrow and will participate in the Global Summit in Paris on March 14-15, 2019 (http://hello-tomorrow.org/summit).
“We see a bright future ahead for cancer patients and it feels terrific that our company is being recognized as a rising star on the global stage,“ says CEO Lao Saal.
Contact: CEO Lao Saal, M.D. Ph.D. email@example.com Phone: +46 (0)70 – 888 52 61
About SAGA Diagnostics
SAGA Diagnostics AB is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.